Ardelyx (ARDX) Competitors

Ardelyx logo
$3.07 -0.02 (-0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$3.06 0.00 (-0.16%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARDX vs. BHC, MOR, RGC, MBX, and PBH

Should you buy Ardelyx stock or one of its competitors? Ardelyx's main competitors and comparable companies include Bausch Health Cos (BHC), MorphoSys (MOR), Regencell Bioscience (RGC), MBX Biosciences (MBX), and Prestige Consumer Healthcare (PBH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ardelyx compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Bausch Health Cos has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Cos$10.27B0.30$157M-$2.29N/A
Ardelyx$407.32M1.91-$61.60M-$0.22N/A

In the previous week, Ardelyx had 22 more articles in the media than Bausch Health Cos. MarketBeat recorded 26 mentions for Ardelyx and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.62 beat Ardelyx's score of 0.09 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bausch Health Cos has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Bausch Health Cos has a net margin of -7.57% compared to Ardelyx's net margin of -11.85%. Ardelyx's return on equity of -35.30% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Cos-7.57% -401.73% 7.34%
Ardelyx -11.85%-35.30%-10.23%

Bausch Health Cos currently has a consensus target price of $8.75, suggesting a potential upside of 4.73%. Ardelyx has a consensus target price of $13.60, suggesting a potential upside of 340.13%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

Summary

Ardelyx beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Ardelyx compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Ardelyx has a consensus price target of $13.60, indicating a potential upside of 340.13%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ardelyx has a net margin of -11.85% compared to MorphoSys' net margin of -226.79%. Ardelyx's return on equity of -35.30% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Ardelyx -11.85%-35.30%-10.23%

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Ardelyx has higher revenue and earnings than MorphoSys. Ardelyx is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Ardelyx$407.32M1.91-$61.60M-$0.22N/A

In the previous week, Ardelyx had 26 more articles in the media than MorphoSys. MarketBeat recorded 26 mentions for Ardelyx and 0 mentions for MorphoSys. Ardelyx's average media sentiment score of 0.09 beat MorphoSys' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Ardelyx Neutral

Summary

Ardelyx beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Regencell Bioscience?

Ardelyx (NASDAQ:ARDX) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Regencell Bioscience has lower revenue, but higher earnings than Ardelyx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$407.32M1.91-$61.60M-$0.22N/A
Regencell BioscienceN/AN/A-$11.70MN/AN/A

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ardelyx had 24 more articles in the media than Regencell Bioscience. MarketBeat recorded 26 mentions for Ardelyx and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.45 beat Ardelyx's score of 0.09 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Regencell Bioscience
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Regencell Bioscience has a net margin of 0.00% compared to Ardelyx's net margin of -11.85%. Regencell Bioscience's return on equity of 0.00% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
Ardelyx-11.85% -35.30% -10.23%
Regencell Bioscience N/A N/A N/A

Ardelyx presently has a consensus target price of $13.60, suggesting a potential upside of 340.13%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Ardelyx has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Summary

Ardelyx beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Ardelyx compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Ardelyx (NASDAQ:ARDX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

MBX Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -11.85%. MBX Biosciences' return on equity of -34.37% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -34.37% -32.72%
Ardelyx -11.85%-35.30%-10.23%

Ardelyx has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A
Ardelyx$407.32M1.91-$61.60M-$0.22N/A

In the previous week, Ardelyx had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 26 mentions for Ardelyx and 24 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.41 beat Ardelyx's score of 0.09 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

MBX Biosciences currently has a consensus price target of $87.30, suggesting a potential upside of 56.06%. Ardelyx has a consensus price target of $13.60, suggesting a potential upside of 340.13%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

58.9% of Ardelyx shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ardelyx beats MBX Biosciences on 11 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Prestige Consumer Healthcare?

Ardelyx (NASDAQ:ARDX) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Ardelyx has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ardelyx had 24 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 26 mentions for Ardelyx and 2 mentions for Prestige Consumer Healthcare. Ardelyx's average media sentiment score of 0.09 beat Prestige Consumer Healthcare's score of -0.18 indicating that Ardelyx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prestige Consumer Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prestige Consumer Healthcare has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$407.32M1.91-$61.60M-$0.22N/A
Prestige Consumer Healthcare$1.09B2.01$190.30M$3.2414.21

Ardelyx currently has a consensus target price of $13.60, indicating a potential upside of 340.13%. Prestige Consumer Healthcare has a consensus target price of $67.00, indicating a potential upside of 45.48%. Given Ardelyx's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ardelyx is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Prestige Consumer Healthcare has a net margin of 13.29% compared to Ardelyx's net margin of -11.85%. Prestige Consumer Healthcare's return on equity of 11.28% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
Ardelyx-11.85% -35.30% -10.23%
Prestige Consumer Healthcare 13.29%11.28%5.25%

Summary

Prestige Consumer Healthcare beats Ardelyx on 9 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$784.28M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9127.37
Price / Sales1.897.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book4.725.144.403.70
Net Income-$61.60M$2.88B$3.52B$392.17M
7 Day Performance4.78%-3.87%-5.34%-4.53%
1 Month Performance-0.65%-3.96%-3.61%-5.86%
1 Year Performance-47.61%-7.13%0.01%-7.78%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDX
Ardelyx
3.5533 of 5 stars
$3.07
-0.6%
$13.60
+343.0%
-47.3%$784.28M$407.32MN/A489
BHC
Bausch Health Cos
2.9049 of 5 stars
$8.40
+2.7%
$8.25
-1.8%
+33.1%$3.12B$10.27BN/A20,300
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28MN/A730
RGC
Regencell Bioscience
0.6278 of 5 stars
$5.63
+6.8%
N/A-60.8%$2.69BN/AN/A10
MBX
MBX Biosciences
2.9294 of 5 stars
$54.06
+5.3%
$87.00
+60.9%
+125.7%$2.53BN/AN/A63

Related Companies and Tools


This page (NASDAQ:ARDX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners